Skip Navigation LinksEspañol (España) > Investigación > Publicaciones > Detalle publicación

 

 

Tumors topple when ERKs uncouple.Tumors topple when ERKs uncouple.Herrero A, Crespo P. Mol Cell Oncol. 2015 Oct 29;3(2):e1091875. eCollection 2016 Mar. 2015-10-28T23:00:00Z<p style="text-align:justify;"><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2"><span class="ms-rteThemeForeColor-2-5 ms-rteThemeFontFace-1 ms-rteFontSize-2" style="font-weight:bold;">Abstract</span><br></span></p><div style="color:#000000;font-family:arial, helvetica, clean, sans-serif;text-align:justify;"><p style="margin-bottom:0.5em;font-size:1.04em;"><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2">Current antitumor therapies targeting the RAS-ERK pathway have been mostly aimed at inhibiting the activity of the kinases that populate the route. A small-molecule inhibitor of ERK dimerization effectively prevents the progression of tumors harboring oncogenic RAS and BRAF, demonstrating that targeting regulatory protein-protein interactions can be a valid strategy for treating RAS-ERK pathway-driven neoplasia.</span><br></p></div><p>​<span style="color:#474f51;font-family:"yanone kaffeesatz";font-size:18px;background-color:#ffffff;">[</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/27308614" style="color:#ed391b;margin:0px;padding:0px;border:0px;font-stretch:inherit;font-size:18px;line-height:inherit;font-family:"yanone kaffeesatz";vertical-align:baseline;background-color:#ffffff;">PubMed</a><span style="color:#474f51;font-family:"yanone kaffeesatz";font-size:18px;background-color:#ffffff;">]</span><br></p>46